ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ARTBIO-Nick-Pullen

More Like This

PR Newswire associated0

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

PR Newswire associated0

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors

Vernal Biosciences Appoints Jim Petrilla as CEO and Board Director. New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver Innovative Therapies Faster. (Photo: Business Wire)

Vernal Biosciences Appoints Jim Petrilla as CEO & Board Director

AskBio Names Mansuo Shannon Chief Scientific Officer

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

BerGenBio Appoints Olav Hellebø as CEO

Chad Swanson, Ph.D., Chief Development Officer, Prothena (Photo: Business Wire)

Prothena Announces Leadership Team Updates

Daniel G. Welch (Photo: Business Wire)

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate